COMPASS Pathways Partners with Worldwide Clinical Trials to Conduct World’s First Large-scale Clinical Trials in Psilocybin Therapy for Treatment-resistant Depression
COMPASS Pathways, a healthcare company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it is partnering with Worldwide Clinical Trials to conduct a major programme of late-stage clinical trials for psilocybin therapy for treatment-resistant depression.
Depression is the leading cause of ill-health and disability worldwide, and one of the fastest growing health problems, affecting more than 300 million people around the world.
George Goldsmith, Executive Chairman and Co-Founder, COMPASS Pathways, said, “We need a new approach to tackling mental health. Current treatments for depression work for many people but there is still a significant unmet need for a large number of patients living with this very challenging condition.
“COMPASS is making rapid progress with plans to develop psilocybin therapy for patients suffering with treatment-resistant depression. Several small, exploratory academic studies have already shown the promise of psychoactive medicine. With Worldwide as our Clinical Research Organisation (CRO) partner, we will have the extensive experience and deep expertise needed to conduct the first ever large-scale randomised, controlled trials, covering 400 patients with treatment-resistant depression in eight countries.”
The trial will begin in the first quarter of 2018 and is planned to include clinical sites in Czech Republic, Finland, Germany, the Netherlands, Norway, Portugal, Spain and the UK.
“The Worldwide team is delighted to have been selected as COMPASS’ CRO partner,” said Peter Benton, President and Chief Operating Officer at Worldwide Clinical Trials. “Worldwide and COMPASS share a commitment to medical and scientific expertise, evidence-based innovation, and new ways of working, centred around the patient. We are looking forward to working together on this exciting new therapy, which could significantly improve the lives and long-term outcomes of patients suffering with treatment-resistant depression.”
The selection of a CRO and development of clinical trial sites are the latest in a series of successful milestones for COMPASS, which completed pre-clinical trials and manufacturing to Good Manufacturing Practice (GMP) standards earlier this year. COMPASS was founded two years ago. The company is backed by a group of accomplished and successful investors, including Christian Angermeyer, Galaxy Investment Partners led by Mike Novogratz and Sam Englebardt, and Peter Thiel. COMPASS is also supported by a team of highly respected expert advisers (see below).
About COMPASS Pathways
COMPASS Pathways is a healthcare company, founded in 2015 to accelerate patient access to evidence-based innovation in mental health. We are developing psilocybin therapy through late-stage clinical trials in the EU and US for patients with treatment-resistant depression. We will improve mental health through the development of new patient care pathways, based on advances in neuroscience, psychotherapy, psychopharmacology, and technology.
COMPASS Pathways expert advisers
Professor Sir Alasdair Breckenridge CBE FRSE
- Former Chairman, UK Medicines & Healthcare products Regulatory Agency
- Chairman, Centre of Regulatory Excellence Advisory Board
Robin Carhart-Harris PhD
- Head of Psychedelic Research, Faculty of Medicine at Imperial College London
- First author on psilocybin clinical trial for treatment-resistant depression, Imperial College (2016)
- Former VP Global Clinical Operations for Europe, Middle East & Africa, Janssen Pharmaceuticals
- Former Associate Director, UK National Institute for Health Research Clinical Research Network
Professor Guy Goodwin FMedSci
- WA Handley Professor of Psychiatry
- Former Chair, Department of Psychiatry, University of Oxford
- Former President, European College of Neuropsychopharmacology
Professor Charles Grob MD
- Director of the Division of Child and Adolescent Psychiatry at the Harbor-UCLA Medical Center
Tom Insel MD
- President and Co-Founder, Mindstrong Health
- Former Lead, Verily Mental Health team
- Former Director, US National Institute of Mental Health
- Vice President of Strategy, WebMD Health Group
- Former Global Head, Janssen Solutions and Janssen Healthcare Innovation
David Nichols PhD
- Professor Emeritus of Pharmacology, Purdue University
Professor Augustus John Rush MD
- Professor Emeritus of University of Texas Southwestern Medical Center and Duke-NUS Graduate Medical School
- Recipient of Thomson Reuters: World’s Most Influential Scientific Minds (2014)
- American Psychiatric Association (APA): Award for Research in Psychiatry (2007)
Paul Summergrad MD
- Chairman, Psychiatry Department, Tufts University School of Medicine
- Former President, American Psychiatric Association
About Worldwide Clinical Trials
Worldwide Clinical Trials employs more than 1,600 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world sees CROs – in the best possible way. From early phase and bioanalytical sciences through late phase and post-approval, we provide world-class, full-service drug development services. With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID) and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. For more information, visit Worldwide.com.
About depression and treatment-resistant depression
- Depression is one of the fastest growing health problems we face today, and the leading cause of ill-health and disability worldwide. At its worst, it can lead to suicide
- The WHO estimates that more than 300 million people worldwide are living with depression, an increase of 18% between 2005 and 2015. Of these, about 100 million people suffer with treatment-resistant depression (TRD)
- Around 25% of people in the EU suffer from anxiety and depression
- The European Brain Council believes that across the EU, the total annual cost of depression is €118 billion
- Patients with TRD are likely to have higher medical costs and be associated with lower productivity and quality of life, for themselves and their families
+44 7966 309024
+44 7850 546135
Worldwide Clinical Trials:
Sherri Stuart, Vice President, Global Marketing and Communications
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
United Nations Climate Action Award Goes to Germany for the First Time11.12.2018 22:00 | Tiedote
Within the context of the United Nations Framework Convention on Climate Change, two ProVeg projects were awarded the Momentum for Change Climate Action Award 2018 in the category Planetary Health. One of these is the health promotion project Aktion Pflanzen-Power, jointly initiated with BKK ProVita. ProVeg and its partner received the award for their work in schools. It marks the first time that this award has gone to Germany. The award ceremony took place yesterday in the Polish city of Katowice as part of the 24th UN Climate Change Conference. ProVeg and BKK ProVita promote children’s health and climate action Aktion Pflanzen-Power aims to improve the availability and quality of vegan and vegetarian dishes in schools. Together with BKK ProVita, ProVeg has so far reached 24,800 students at 41 schools throughout Germany on the subject of wholesome, plant-based nutrition as part of the health promotion project. Healthy nutrition with Aktion Pflanzen-Power Andreas Schöfbeck, member of t
Thales and Gemalto are granted regulatory clearance by the European Commission11.12.2018 20:01 | Tiedote
Regulatory News: Reference is made to the joint press release by Thales (Euronext Paris: HO) and Gemalto (Euronext Amsterdam and Paris: GTO) dated 27 March 2018 in relation to the launch of the recommended all-cash offer by Thales for all the issued and outstanding shares of Gemalto (the “Offer”), the publication of the Offer Document, and the joint press release of Thales and Gemalto dated 10 August 2018 in relation to the further extension of the Acceptance Period. Terms not defined in this press release will have the meaning as set forth in the Offer Document. Thales and Gemalto announce today that they have been granted merger control Regulatory Clearance by the European Commission, following Thales’s commitment to divest its general purpose hardware security modules (GP HSM) business globally1 to a suitable purchaser. This clearance is effective immediately. Together with the merger control clearances obtained in China, Israel, South Africa and Turkey, and clearances relating to f
Starr Insurance Companies Expands Aviation Insurance Operations to Brazil11.12.2018 18:43 | Tiedote
Starr Insurance Companies today announced that Starr International Brasil Seguradora S.A. (“Starr Brazil”) has been granted a local license to offer aviation insurance. “We are thrilled to be adding aviation capability in an important, growing economy like Brazil,” stated Steve Blakey, president and chief executive officer for Starr Insurance Holdings, Inc. “As a worldwide leader in aviation insurance solutions, we are constantly seeking new opportunities and markets to meet the growing needs of the aviation and aerospace industry around the globe.” Fernanda Strachino, aviation specialist underwriter, has joined Starr Brazil to head the new aviation division. Fernanda brings more than 16 years’ of experience in the aviation and insurance market. Starr Brazil will offer a variety of aviation coverages, including: Aircraft Hull & Liability; Spare Parts; Third-Party Legal Liability; Corporate Non-Owned Aircraft Liability; General Liability; RETA Insurance (Mandatory Liability), Hangarkeep
Andersen Global Continues Growth in United Kingdom With Claritas Tax Limited11.12.2018 17:30 | Tiedote
Today, Andersen Global expanded its reach in the United Kingdom with the addition of Claritas Tax Limited, a tax advisory and compliance services firm based in Birmingham, the second largest city in the country. Claritas is the fourth firm collaborating with Andersen Global in the UK. “Adding a sought-after firm like Claritas is not only a logical extension for Andersen Global, but it broadens our offering in the UK. Their practice focuses on corporation tax, R&D tax reliefs, mergers and acquisitions, private equity and venture capital in addition to serving individuals,” said Mark Vorsatz, Andersen Global Chairman and Andersen Tax LLC CEO. “Iain Wright and his team enhance our already robust core competences in the UK, a critical market for our clients, and we look forward to working with Claritas on a number of upcoming corporate opportunities.” Founded in 2012, Claritas Tax Limited is an advisory led business that provides a full range of tax advisory and compliance services to entr
Seoul Semiconductor Wins Patent Litigation against Everlight in Germany and Is Awarded Statutory Litigation Costs11.12.2018 17:00 | Tiedote
Seoul Semiconductor Co., Ltd. (KOSDAQ:046890) (“Seoul”), a leading global innovator of LED products and technology, announced that it won a patent litigation against Everlight Electronics Co., Ltd. (“Everlight”) in Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181211005233/en/ Seoul Semiconductor's Headquarters in Korea (Photo: Business Wire) The patent involved in this litigation relates to an LED package structure for thermal dissipation. Everlight purchased this patent from a U.S. company in 2017, and subsequently brought a patent lawsuit against Seoul in the Manheim Court of Germany. In December 2018, however, the Manheim Court ruled in favor of Seoul and ordered that Everlight, as the losing party, should bear the statutory costs of the court proceeding. In the United Kingdom, Seoul had already won a patent litigation against Everlight earlier this year. At that time, the UK Patent Court also ordered that Ever
The O-RAN Alliance Announces New Board Members11.12.2018 17:00 | Tiedote
The O-RAN Alliance announced today that Reliance Jio, TIM, and Verizon have joined the O-RAN board. “It’s encouraging to see the O-RAN Alliance off to such a strong start and gaining momentum as we welcome three new board members. It’s important that the wireless industry continues to come together to drive forward O-RAN’s goals for open networking, software, and virtualization in global wireless networks especially as 5G is closer than ever,” said Andre Fuetsch, Chairman of the O-RAN Alliance, President-AT&T Labs and CTO of AT&T. “This is a great opportunity for the Service Provider Industry as network, services and applications leverage cloud native platforms and the right time to fundamentally transform the RAN infrastructure and platforms. We look forward to working closely with the O-RAN Alliance in the acceleration and adoption of open, intelligent, and programmable RAN architectures that can clearly disrupt the building blocks of 5G and beyond,” said Mathew Oommen, President, Re
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme